A couple of drugmakers are celebrating this week after favorable decisions from England’s cost watchdog. The National Institute for Health and Care Excellence has recommended both Eli Lilly’s Taltz and Pfizer’s Besponsa. More: Pfizer's Besponsa, Lilly's Taltz rack up reimbursement
read moreJanssen ranks first in new survey of pharma’s reputation among mental health patient groups More: Pharma lacks engagement with mental health groups: report Source: News
read moreAfter failing to reach a pricing deal on Orkambi for nearly three years, Vertex has declined to submit data on a new CF drug to England’s NICE for appraisal. More: Amid pricing spat with U.K. government, Vertex declines to submit
read morePharmaTimes Media has announced the Medical & Scientific Excellence Awards as the latest addition to its highly prestigious portfolio of events. More: Medical & Scientific Advisors to get the recognition they deserve Source: News
read moreThe PharmaTimes Communications Team of the Year competition is the only pharma industry awards that tests the competencies and potential of communications agency teams, benchmarking talent agency side. This year sees the introduction of a new ‘Charity Challenge’, which in
read moreDirector of policy and communications at MSD and executive steering group member Harry Brady looks at how the PharmaTimes Marketer and Communications Team of the Year competitions have evolved to embrace the importance of cross-functional working and the value of
read more© 1994 - 2026 B.M. Pharmaceuticals